Integration of genetic, clinical, and INR data to refine warfarin dosing (Q33550741)

28 July 2017

title

Integration of genetic, clinical, and INR data to refine warfarin dosing (English)

1 reference

28 July 2017

1 reference

29

1 reference

28 July 2017

P E Milligan

20

0 references

Munir Pirmohamed

object named as

M Pirmohamed

6

0 references

Mia Wadelius

2

object named as

M Wadelius

1 reference

28 July 2017

P Lenzini

1

1 reference

28 July 2017

S Kimmel

3

1 reference

28 July 2017

J L Anderson

4

1 reference

28 July 2017

A L Jorgensen

5

1 reference

28 July 2017

M D Caldwell

7

1 reference

28 July 2017

N Limdi

8

1 reference

28 July 2017

J K Burmester

9

1 reference

28 July 2017

M B Dowd

10

1 reference

28 July 2017

P Angchaisuksiri

11

1 reference

28 July 2017

A R Bass

12

1 reference

28 July 2017

J Chen

13

1 reference

28 July 2017

N Eriksson

14

1 reference

28 July 2017

A Rane

15

1 reference

28 July 2017

J D Lindh

16

1 reference

28 July 2017

J F Carlquist

17

1 reference

28 July 2017

B D Horne

18

1 reference

28 July 2017

G Grice

19

1 reference

28 July 2017

C Eby

21

1 reference

28 July 2017

J Shin

22

1 reference

28 July 2017

H Kim

23

1 reference

28 July 2017

D Kurnik

24

1 reference

28 July 2017

C M Stein

25

1 reference

28 July 2017

G McMillin

26

1 reference

28 July 2017

R C Pendleton

27

1 reference

28 July 2017

R L Berg

28

1 reference

28 July 2017

B F Gage

30

1 reference

28 July 2017

language of work or name

English

0 references

publication date

7 April 2010

1 reference

Clinical Pharmacology & Therapeutics

28 July 2017

published in

1 reference

28 July 2017

volume

87

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

572-578

1 reference

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

The largest prospective warfarin-treated cohort supports genetic forecasting

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

CYP4F2 genetic variant alters required warfarin dose

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Use of genetic and nongenetic factors in warfarin dosing algorithms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Incidence of fatal adverse drug reactions: a population based study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Warfarin: almost 60 years old and still causing problems

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

National surveillance of emergency department visits for outpatient adverse drug events

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Systematic overview of warfarin and its drug and food interactions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Heparin-induced increase in the international normalized ratio. Responses of 10 commercial thromboplastin reagents.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

A formula to estimate the approximate surface area if height and weight be known. 1916.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Incidence and predictors of severe bleeding during warfarin treatment.

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Genetic testing for warfarin dosing? Not yet ready for prime time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Factors affecting warfarin therapy following cardiac valve surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Increased sensitivity to warfarin after heart valve replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

A randomized trial comparing 5-mg and 10-mg warfarin loading doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.13

Five-day food intake in elderly female outpatients with Parkinson's disease, rheumatoid arthritis or stroke.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2858245

Exaggerated initial response to warfarin following heart valve replacement

31 October 2018

1 reference

12 December 2020

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy

1 reference

12 December 2020

The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

1 reference

12 December 2020

Genetic modulation of oral anticoagulation with warfarin

1 reference

12 December 2020

Identifiers

DOI

10.1038/CLPT.2010.13

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference